RYTM News and Press, Rhythm Pharmaceuticals Inc. From 06/07/23

BOSTON, June 07, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway dis...

2023-06-04 12:00:08 ET Billions of dollars in sales across various MedTech markets will be at stake if there is a broader acceptance of weight loss drugs developed by Novo Nordisk ( NVO ) and Eli Lilly ( NYSE: LLY ), Morgan Stanley argued in a research note last week. Novo N...

2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...

BOSTON, May 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway dise...

2023-05-08 08:53:22 ET Rhythm Pharmaceuticals ( NASDAQ: RYTM ) announced Monday that Health Canada approved its weight management agent Imcivree as a subcutaneous injection for patients aged six years and older with certain rare genetic diseases of obesity. Accordingly, Imcivr...

-- First and only approved therapy in Canada that targets genetic impairment in the MC4R pathway - a root cause of early-onset, severe obesity in these patients – -- Approval granted following a Priority Review by Health Canada – BOSTON, May 08, 2023 (GLOBE NEWSWIRE)...

2023-05-07 12:00:27 ET Patients in the U.S are expected to dish out $10B on obesity medicines in 2027, marking an $8.1B rise or over 378% growth for the period 2023 – 2027, the latest industry report on pharma spending from the drug analytics firm IQVIA Holdings ( IQV ) indicates...

2023-05-03 02:18:02 ET Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2023 Earnings Conference Call May 2, 2023 8:00 A.M. ET Company Participants David Connolly - Executive Director of Investor Relations and Corporate Communications David Meeker - Chairman, President, and Ch...

2023-05-02 07:15:41 ET Rhythm Pharmaceuticals press release ( NASDAQ: RYTM ): Q1 GAAP EPS of -$0.92 misses by $0.21 . Revenue of $11.5M (+671.8% Y/Y) misses by $0.62M . As of March 31, 2023, cash, cash equivalents and short-term investments were approximately $...

-- Strong U.S. commercial progress continues for IMCIVREE ® (setmelanotide) with more than 300 new prescriptions for Bardet-Biedl syndrome (BBS) received since FDA approval -- -- Launched IMCIVREE for BBS in Germany with federal reimbursement -- -- First patient...